Researchers at the Massachusetts Institute of Technology (MIT) have unveiled a groundbreaking vaccine adjuvant designed to bolster the effectiveness of the injectable polio vaccine (IPV), enabling it to induce a powerful immune response within the gastrointestinal (GI) tract. This critical development holds the potential to overcome a significant hurdle in the global campaign to eradicate polio: the IPV’s inability to prevent the transmission of the virus, a feature previously exclusive to the oral polio vaccine (OPV) but without OPV’s associated risks. The new nanoparticle-based adjuvant, when administered with the standard IPV, demonstrated a remarkable 20-fold increase in the production of crucial antibodies for mucosal immunity in rat studies, offering a dual advantage of preventing paralytic disease and blocking viral shedding.
The Enduring Challenge of Polio Eradication
Polio, a highly contagious infectious disease caused by the poliovirus, primarily affects young children. The virus invades the nervous system and can cause irreversible paralysis within hours, and in some cases, death. Historically, polio devastated communities worldwide, causing widespread fear and disability. The global effort to eradicate polio began in earnest in 1988 with the launch of the Global Polio Eradication Initiative (GPEI) by the World Health Organization (WHO), UNICEF, Rotary International, the U.S. Centers for Disease Control and Prevention (CDC), and the Bill & Melinda Gates Foundation. This ambitious campaign has driven down polio cases by over 99% since then, from an estimated 350,000 cases in more than 125 endemic countries in 1988 to only a few hundred cases annually in recent years.
The success of the eradication program has largely relied on two types of vaccines: the inactivated polio vaccine (IPV) and the oral polio vaccine (OPV). IPV, developed by Jonas Salk in the 1950s and typically administered via injection, contains killed poliovirus. It is highly effective at preventing paralytic disease by generating systemic immunity (antibodies in the bloodstream), but it does not effectively prevent the virus from replicating in the gut and being shed in feces. This means vaccinated individuals, while protected from paralysis, can still carry and transmit the virus, especially in communities with poor sanitation.
The OPV, developed by Albert Sabin, uses live, attenuated (weakened) poliovirus. It is administered orally, making it easy to deploy in mass vaccination campaigns. Crucially, OPV induces a robust mucosal immune response in the GI tract, mimicking natural infection and effectively preventing both paralytic disease and viral transmission. This mucosal immunity is vital because poliovirus primarily spreads through contaminated food and water via the fecal-oral route, meaning the GI tract is the primary site of infection and replication. However, OPV carries a small but significant risk: in extremely rare instances, the live attenuated virus can mutate back into a virulent form, causing vaccine-derived poliovirus (VDPV), which can lead to paralysis in unvaccinated individuals or those with weakened immune systems. This risk has led many countries, particularly those with high vaccination coverage and no wild poliovirus circulation, to switch to IPV or use sequential IPV/OPV schedules.
"People who are vaccinated with the injectable vaccine are not getting sick, but they may be helping the virus circulate. Mucosal immunity could help lower that shedding and ideally eliminate it," explained Ana Jaklenec, a principal investigator in MIT’s Koch Institute for Integrative Cancer Research and a senior author of the study. This critical observation underscores the urgent need for an IPV that can also induce mucosal immunity, thus combining the safety of IPV with the transmission-blocking power of OPV.
A Novel Approach to Mucosal Immunity
The MIT researchers, in collaboration with colleagues at Harvard Medical School, focused on a derivative of vitamin A, known as Am80, which had previously shown promise as a vaccine adjuvant for stimulating immune cells to migrate to the GI tract. While effective, Am80 previously required multiple daily injections to elicit a strong immune response, rendering it impractical for widespread vaccination campaigns. To overcome this limitation, the research team set out to develop a sustained-release formulation.
Their solution involved encapsulating Am80 within lipid nanoparticles (LNPs), a delivery platform gaining prominence in vaccine technology, notably in mRNA vaccines. After testing various nanoparticle formulations, lipid nanoparticles proved most effective at ensuring the slow and continuous release of Am80 over several days from a single injection. "The purpose of the nanoparticle is making sure that we can engineer a platform with a sustained release of the cargo for a few days," added Behnaz Eshaghi, an MIT postdoc and the lead author of the paper published in Science Advances. "That way we can overcome the bottleneck that for free administration of Am80 you need multiple daily injections."
In their study, rats were given an injection of the inactivated polio vaccine, similar to the one used in the United States, alongside a separate injection of Am80 encapsulated in LNPs. Booster doses were administered at four and eight weeks. The results were compelling: the nanoparticles accumulated in the lymph nodes, where they interacted with B and T cells simultaneously exposed to the polio vaccine antigens. This interaction spurred the B and T cells to produce specific surface proteins that act as "homing signals," directing them to the GI tract’s mucosal lining.
Once in the GI tract, these activated B cells began producing immunoglobulin A (IgA) antibodies, which are crucial for protecting mucosal surfaces from infection by coating the membranes. In addition, the rats also produced immunoglobulin G (IgG) antibodies, which circulate in the bloodstream and are typically generated in response to standard IPV, providing systemic protection against paralytic disease. This dual antibody response – both mucosal IgA and systemic IgG – represents a significant advancement. The researchers observed a 20-fold increase in the type of antibodies needed for mucosal immunity compared to IPV administered without the adjuvant.
"IPV is a safe vaccine, but it cannot create mucosal immunity. OPV can create that mucosal response, but it is not as safe," Eshaghi stated. "By adding Am80 to lipid nanoparticle as an adjuvant, we are combining the safety of IPV with an adjuvant that can produce the mucosal immunity that normally you can only get with OPV." Robert Langer, the David H. Koch Institute Professor at MIT and a senior author of the study, highlighted the transformative potential of this approach.
A Timeline of Polio Eradication Efforts and Persistent Challenges
The journey to eradicate polio has been long and arduous, marked by scientific breakthroughs and persistent global health challenges.
- 1950s: Dr. Jonas Salk develops the first effective injectable polio vaccine (IPV) in 1955. Dr. Albert Sabin develops the oral polio vaccine (OPV) in the late 1950s, which becomes widely available in the early 1960s.
- 1988: The Global Polio Eradication Initiative (GPEI) is launched, aiming to eradicate polio by the year 2000. At this time, wild poliovirus was endemic in over 125 countries, causing an estimated 350,000 cases annually.
- 1994: The Americas are certified polio-free.
- 2000: The Western Pacific Region is certified polio-free.
- 2002: The European Region is certified polio-free.
- 2012: India, once considered the epicenter of polio, records its last case of wild poliovirus.
- 2015: Wild poliovirus type 2 (WPV2) is declared eradicated globally. This allows for a synchronized global switch from trivalent OPV (tOPV, protecting against types 1, 2, and 3) to bivalent OPV (bOPV, protecting against types 1 and 3) to eliminate the risk of VDPV2.
- 2019: Wild poliovirus type 3 (WPV3) is declared eradicated globally. Only wild poliovirus type 1 (WPV1) remains in circulation.
- 2020: The African Region is certified polio-free of WPV1.
- Current Status (2023-2024): Wild poliovirus type 1 remains endemic in only two countries: Afghanistan and Pakistan. However, outbreaks of circulating vaccine-derived poliovirus (cVDPV) continue to pose a significant threat in various regions, including parts of Africa, the Middle East, and even isolated cases in developed nations like the United States and the United Kingdom, detected through wastewater surveillance. In 2022, for example, there were 143 cases of WPV1 and 552 cases of cVDPV, highlighting the persistent challenges.
The detection of poliovirus in wastewater in countries with high IPV vaccination rates underscores the problem of asymptomatic shedding. Even if individuals are protected from paralysis by IPV, they can still shed the virus, contributing to its circulation and potentially exposing unvaccinated populations. This phenomenon prolongs the eradication effort and necessitates a vaccine that not only protects individuals but also interrupts community-level transmission.
Implications for Global Health and Beyond
The development of an IPV-plus-adjuvant vaccine that induces mucosal immunity could dramatically accelerate the final push for polio eradication. By offering a safe, injectable vaccine that prevents both disease and transmission, it would eliminate the reliance on OPV, thereby removing the risk of cVDPV. This would allow for a unified, safer global vaccination strategy, simplifying logistics and reducing public health complexities. For countries like Afghanistan and Pakistan, where polio remains endemic and vaccination efforts face significant challenges, a truly transmission-blocking IPV could be a game-changer, helping to build robust herd immunity without the risk of generating new outbreaks.
The implications of this research extend far beyond polio. The innovative approach of using lipid nanoparticles to deliver an adjuvant that directs immune cells to mucosal surfaces could revolutionize vaccine development for a wide array of other infectious diseases. Many pathogens, including those causing respiratory infections (like influenza, RSV, or even future coronaviruses), sexually transmitted infections, or other gastrointestinal diseases (such as rotavirus or norovirus), primarily enter the body through mucosal membranes. Current injectable vaccines for these pathogens often provide systemic immunity but may not offer strong protection at the initial entry points, leading to continued transmission or milder forms of disease.
"You could potentially add it to any vaccine that’s injected," Jaklenec concluded. "This particular work shows that cells can be directed to the gut and increase enteric mucosal immunity. Whether it works for the respiratory or vaginal mucosa is not yet clear." This statement opens avenues for exploring similar adjuvant strategies for vaccines targeting other mucosal surfaces, potentially leading to more effective and broadly protective vaccines against a host of global health threats.
Future Directions and Challenges
While the findings from the rat study are highly promising, significant steps remain before this new vaccine can impact global health. The immediate next phase involves testing the vaccine in larger animal models, where the vaccine and adjuvant will be pre-mixed and injected together, mimicking a more practical vaccine formulation. Following successful preclinical trials, the research will need to advance to human clinical trials to assess safety, immunogenicity, and efficacy in humans.
Further challenges include scaling up the manufacturing of the lipid nanoparticle adjuvant and integrating it with existing IPV production lines, ensuring cost-effectiveness to make it accessible to low-income countries that bear the brunt of polio outbreaks, and navigating complex regulatory approval processes worldwide. The Global Polio Eradication Initiative and its partners would undoubtedly welcome such an innovation, provided it meets stringent safety and efficacy standards, as it represents a crucial tool in achieving the long-awaited goal of a polio-free world. This scientific breakthrough from MIT offers a beacon of hope, bringing humanity closer to consigning polio to the history books, much like smallpox before it.
